Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms which arise from neuroendocrine cells that are distributed widely throughout the body. Although heterogenous, many of them share their ability to overexpress somatostatin receptors (SSTR) on their cell surface. Due to this, SSTR and somatostatin have been a large subject of interest in the discovery of potential biomarkers and treatment options for the disease. The aim of this review is to describe the molecular characteristics of somatostatin and somatostatin receptors and its application in diagnosis and therapy on patients with NENs as well as the use in the near future of somatostatin antagonists.

Automated summary

Neuroendocrine neoplasms (NENs) are heterogeneous tumors arising from neuroendocrine cells, many of which overexpress somatostatin receptors (SSTR). As a result, somatostatin and SSTR are important subjects of research for potential biomarkers and treatment options, including the use of somatostatin antagonists in the future.